Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With… (NCT06359873) | Clinical Trial Compass
CompletedNot Applicable
Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension
China58,427 participantsStarted 2022-05-01
Plain-language summary
Based on the data of inpatients with hypertension and a cross-sectional study with a large sample size, this study aims to find the early warning value of the left anteroposterior atrial diameter for the possible occurrence of atrial fibrillation in patients with hypertension, and compare the advantages and disadvantages of the above two methods for the early warning of the risk of atrial fibrillation in patients with hypertension, so as to achieve the purpose of early identification of high-risk groups that may develop atrial fibrillation.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with a diagnosis of primary hypertension using the current or past medical history.
* Availability of one or more complete ECG and 24h holter data.
* Availability of complete echocardiogram data in the current hospitalization.
Exclusion Criteria:
* Patients under 18 years of age.
* Cases with incomplete or unidentifiable results from extracted data.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
left atrial diameter (LAD)
Timeframe: Data collection was completed after discharge from the hospital, up to 3 months.
2
CHA2DS2-VASc score
Timeframe: Data collection was completed after discharge from the hospital, up to 3 months.
3
C2HEST score
Timeframe: Data collection was completed after discharge from the hospital, up to 3 months.
4
Atrial fibrillation (AF)
Timeframe: Data collection was completed after discharge from the hospital, up to 3 months.
Trial details
NCT IDNCT06359873
SponsorThe Second Affiliated Hospital of Chongqing Medical University